Par Drugs & Chemicals Ltd

Stock Opportunities Untested - but worth a good look
1

Overview
Par Drugs & Chemicals makes API’s & Fine Chemicals for domestic as well as Exports Market

Business
They have 2 business verticals namely - APIs & Fine Chemicals. 72% of Revenue comes from APIs & rest 28% from Fine Chemicals

APIs

In APIs the company makes APIs for Formulation Manufacturers. For example when a drug is formed their are many steps to it. First is KSM which is key starting material then comes your intermediate after that API and then at the end comes Formulation which is also called Finished Dosage.

It has entire range of Antacid Molecules. Antacid Means a medicine that prevents Acidity. Currently they have around 18 APIs molecules , As follows-

image
image1197×581 121 KB

The company is one of the largest manufacturer in Magnesium Hydroxide, Sucralfate and
Magnesium Trisilate in India. Their uses are stated above in the Image. So basically they are a End-to-End Antacid Solution Provider. With many APIs that cater to same segment.

Fine Chemicals

Coming to Fine Chemicals. Unlike APIs fine chemicals have uses in many Sectors such as Pharmaceuticals, Adhesives , Agricultural etc etc

Currently company has around 10 fine chemicals portfolio, Which looks like this -

image
image1193×492 75 KB

As you can see they have variety of uses

Capacity

Company has around 9,700 MT Capacity in Bhavnagar for APIs, Fine Chemicals & Magnesium Hydroxide.

image
image1203×542 91.2 KB

Company also doing a 1,400 MTPA Brownfiled CAPEX in 2021 , which will add put to their capacity

Customers

Company caters to around 132 Customers & Added 20 New Customers in FY21 .Its key customers include Essential Drugs Company, Pfizer, United Phosphorus, Cipla.

R&D

The company mentioned that its R&D Team is focusing on Chronic therapies like
antidepressants, anti-diabetic and anti-bacterial. This shows that they are also entering newer & newer Therapeutic Segments & Expanding their Product Portfolio.

Financials

Financials as such looks good in FY21 Numbers -

EBITDA Margin - 26%

PAT Margin - 19%

ROCE - 22%

image
image1177×572 147 KB

Risks

Risks in this business can be -

  • Over Dependency on Antacid Products
  • Lack of Execution of Management in terms of diversifying Product Portfolio & Capacity Expansion

Disclosure - Not Yet Invested

Here were my 2 Cents of the company. Thanks for reading & Giving your valuable time

Sources used in this Thread was Investor Presentation of the Company.

Link for it is this -

20 Likes
2

@Jay_shankarpure Thanks for the details.

Few observations from my end.

a. They are enjoying one of the best operating profit margins in the industry with marquee client base.
b. Set up a new R&D for diversification into antidepressants, anti-diabetic and anti-bacterial just to reduce the dependence on Antacid products.
c. Expanded brownfield capacity to reflect in higher revenues and profits
d. Its a debt free & high promoter holding company and continues to impress on the financial ratios.
f. As per insider trading data, Promoters were indeed busy shopping their shares during Dec 2021.
g. All the expansions including R&D was setup using internal accruals.
h. The management is confident of adding another greenfield capacity in the next 2-3 years.
i. As per last intimation in Dec 2021, the company had entered into an agreement with a German trading company to increase global presence.

Discl: Invested at low levels

11 Likes
3
4
5

Here are some risks in the business pointed out by @dineshssairam Sir

5 Likes
6

The stated objective of IPO was.

image

7

I didn’t say it wasn’t in the DRHP.

  1. Working Capital Requirements were tame before the IPO and seems to have become tame after it. But in between — just for a year — there was a massive increase in requirement and an IPO was done just to take care of it. Sounds really odd. I doubt I’ve seen an IPO just to take care of 1 year’s worth of Working Capital.

  2. Also see the point on the Promoters acquiring a chunk of the company (+35% over their previous stake and almost 16% of Pre IPO size) just before the IPO.

  3. Also see the Related Party Transactions, where Directors are given regular loans.

  4. The Annual Report available in their website is detailed only in 2019-20 (Year of the IPO). Before and after it, they’ve given only the bare minimum (Which I presume is their MCA filing). This makes it difficult to analyse the company in detail.

Again, these may not be fishy in the end. I’m just asking questions. If you are able to answer them satisfactorily for yourself, good on you.

13 Likes
8

Can you give me the ball park figures for investment in this company?

9

Update on this. Please!!

10

Where did you find more details on diversification

11

Refer their last investor presentation available on the exchanges.

12

The stock has gone down 25 percent and results are neutral it seems.Not sure what is going on

3 Likes